These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 16899108)

  • 61. Interleukin-6 in renal disease and therapy.
    Jones SA; Fraser DJ; Fielding CA; Jones GW
    Nephrol Dial Transplant; 2015 Apr; 30(4):564-74. PubMed ID: 25011387
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Blockade of co-stimulation in chronic inflammatory diseases.
    Scheinecker C
    Wien Med Wochenschr; 2015 Jan; 165(1-2):23-7. PubMed ID: 25271110
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Weight change during pharmacological blockade of interleukin-6 or tumor necrosis factor-α in patients with inflammatory rheumatic disorders: a 16-week comparative study.
    Younis S; Rosner I; Rimar D; Boulman N; Rozenbaum M; Odeh M; Slobodin G
    Cytokine; 2013 Feb; 61(2):353-5. PubMed ID: 23228348
    [TBL] [Abstract][Full Text] [Related]  

  • 64. IL-6 blockade in chronic inflammatory diseases.
    Puchner A; Blüml S
    Wien Med Wochenschr; 2015 Jan; 165(1-2):14-22. PubMed ID: 25335457
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeting the inflammasome in rheumatic diseases.
    McCoy SS; Stannard J; Kahlenberg JM
    Transl Res; 2016 Jan; 167(1):125-37. PubMed ID: 26118952
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Anti-interleukin 6 receptor antibody treatment in rheumatic disease.
    Nishimoto N; Kishimoto T; Yoshizaki K
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i21-7. PubMed ID: 11053081
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 5. B cell targeting biologics for rheumatic diseases].
    Saito K; Tanaka Y
    Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2991-7. PubMed ID: 22175143
    [No Abstract]   [Full Text] [Related]  

  • 68. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment.
    Nishida S; Hagihara K; Shima Y; Kawai M; Kuwahara Y; Arimitsu J; Hirano T; Narazaki M; Ogata A; Yoshizaki K; Kawase I; Kishimoto T; Tanaka T
    Ann Rheum Dis; 2009 Jul; 68(7):1235-6. PubMed ID: 19525413
    [No Abstract]   [Full Text] [Related]  

  • 69. Uneventful splenectomy and cholecystectomy in a patient treated with anti-interleukin-6 receptor antibody therapy.
    Ishizaki M; Sasada T; Kunitomi A; Konaka Y; Yagita M; Gunji S; Kanai M; Nishimoto N; Takabayashi A
    Langenbecks Arch Surg; 2008 May; 393(3):423-5. PubMed ID: 17703320
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Current and novel anti-inflammatory drug targets for inhibition of cytokines and leucocyte recruitment in rheumatic diseases.
    Szollosi DE; Manzoor MK; Aquilato A; Jackson P; Ghoneim OM; Edafiogho IO
    J Pharm Pharmacol; 2018 Jan; 70(1):18-26. PubMed ID: 28872680
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Chemokines in rheumatic diseases: pathogenic role and therapeutic implications.
    Miyabe Y; Lian J; Miyabe C; Luster AD
    Nat Rev Rheumatol; 2019 Dec; 15(12):731-746. PubMed ID: 31705045
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Off-label use of anti-IL-1 drugs in rheumatic diseases.
    Stefania S; Colia R; Cinzia R; Corrado A; Cantatore FP
    Int J Immunopathol Pharmacol; 2021; 35():20587384211006584. PubMed ID: 33855881
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases.
    Gabay C; McInnes IB
    Arthritis Res Ther; 2009; 11(3):230. PubMed ID: 19519923
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Type I interferon in rheumatic diseases.
    Muskardin TLW; Niewold TB
    Nat Rev Rheumatol; 2018 Mar; 14(4):214-228. PubMed ID: 29559718
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Garden of therapeutic delights: new targets in rheumatic diseases.
    Waldburger JM; Firestein GS
    Arthritis Res Ther; 2009; 11(1):206. PubMed ID: 19232066
    [TBL] [Abstract][Full Text] [Related]  

  • 76. IL-27 and autoimmune rheumatologic diseases: The good, the bad, and the ugly.
    Shahi A; Afzali S; Salehi S; Aslani S; Mahmoudi M; Jamshidi A; Amirzargar A
    Int Immunopharmacol; 2020 Jul; 84():106538. PubMed ID: 32361567
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Biologic agents in the treatment of inflammatory rheumatic diseases.
    Kalden JR; Manger B
    Curr Opin Rheumatol; 1998 May; 10(3):174-8. PubMed ID: 9608318
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Advances in antibody engineering for rheumatic diseases.
    Schmid AS; Neri D
    Nat Rev Rheumatol; 2019 Apr; 15(4):197-207. PubMed ID: 30814691
    [TBL] [Abstract][Full Text] [Related]  

  • 79. IL-6: from laboratory to bedside.
    Kishimoto T
    Clin Rev Allergy Immunol; 2005 Jun; 28(3):177-86. PubMed ID: 16129902
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Personalized medicine in cytokine-targeted therapy].
    Behrens F; Köhm M
    Z Rheumatol; 2013 Feb; 72(1):41-8. PubMed ID: 23392600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.